Sevion Therapeutics, Inc. Announces Close of Private Placement Financing for Gross Proceeds of Approximately $6.55 Million

Aug 03, 2015 OTC Disclosure & News Service, SVON, OTCQB -Sevion Therapeutics, Inc. ( Sevion or the Company ) (OTCQB:SVON) today announced that on July 27, 2015 the Company closed a private placement with certain accredited investors (the “Offering”) whereby the Company sold units consisting of shares common stock or convertible preferred stock of the Company and warrants to purchase shares of common stock for aggregate gross proceeds of approximately $6,548,963. Each share of the convertible preferred stock is initially convertible into 10 shares of common stock. The warrants will have an exercise price of $1.50 per share, and will expire 30 months from the closing date, though they are exercisable in whole or in part at any time prior to expiration. Laidlaw & Company (UK) Ltd. acted as placement agent for the Offering. Investors in the Offering included certain affiliates of the Company’s Board of Directors (the “Board”), including Opko Health, Inc., of which Dr. Phillip Fr

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: